SWM
RYTM icon

Spire Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Spire Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$22K – 2911
2021
Q1 		$22K Buy
+1,000
New +$29K ﹤0.01% 2112

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Spire Wealth Management's RYTM Position: Q2 2021 in Review

Spire Wealth Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2021, closing a stake of 1,000 shares — an estimated $22K sold.

Spire Wealth Management first reported a position in RYTM in Q1 2021 and held it in 1 quarter. The position peaked at $22K in Q1 2021. 105 funds tracked by Wall St. Rank hold RYTM as of Q2 2021.

  • Spire Wealth Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Spire Wealth Management sold 1,000 Rhythm Pharmaceuticals shares in Q2 2021, an estimated $22K.
  • Spire Wealth Management first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Spire Wealth Management's Rhythm Pharmaceuticals position peaked at $22K in Q1 2021.
  • 105 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.